Moderna, Inc. (NASDAQ:MRNA) Receives $67.26 Consensus Target Price from Brokerages

Shares of Moderna, Inc. (NASDAQ:MRNA) have received a consensus rating of “Hold” from the twenty-three brokerages that are currently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $67.26.

Several equities analysts have recently commented on the stock. Bank of America reaffirmed an “underperform” rating and set a $41.00 price target on shares of Moderna in a research report on Tuesday, December 10th. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and cut their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Friday, November 8th. Morgan Stanley cut their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 15th. Finally, UBS Group cut their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th.

Moderna Stock Performance

NASDAQ:MRNA opened at $34.98 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The firm has a 50-day moving average of $40.42 and a two-hundred day moving average of $59.05. The stock has a market cap of $13.46 billion, a P/E ratio of -6.01 and a beta of 1.59. Moderna has a 1-year low of $31.94 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The business had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter last year, the company posted ($1.39) earnings per share. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, research analysts expect that Moderna will post -9.18 earnings per share for the current fiscal year.

Insider Activity at Moderna

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 2,664 shares of company stock worth $115,210 over the last quarter. 15.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Axiom Advisory LLC boosted its holdings in Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock worth $847,000 after buying an additional 198 shares in the last quarter. Arkadios Wealth Advisors boosted its holdings in Moderna by 2.2% during the third quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after buying an additional 243 shares in the last quarter. Knuff & Co LLC boosted its holdings in Moderna by 5.4% during the third quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after buying an additional 244 shares in the last quarter. Stephens Inc. AR boosted its holdings in Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock worth $223,000 after buying an additional 245 shares in the last quarter. Finally, Mather Group LLC. boosted its holdings in Moderna by 25.7% during the third quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after buying an additional 262 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.